Keyphrases
Gene Therapy
100%
Cerebrospinal Fluid
100%
Functional Correction
100%
Mucopolysaccharidosis Type IIIB
100%
Enzymatic Activity
75%
AAV9
75%
Lysosomal Storage Disease
50%
Central Nervous System
50%
N-acetylglucosaminidase
50%
Clinical Development
25%
Healthy Animals
25%
Gene Expression
25%
Novel Therapeutics
25%
Liver
25%
Neuroinflammation
25%
Nave
25%
Blood-brain Barrier
25%
Target Organ
25%
Canine
25%
High Concentration
25%
Activity Level
25%
Whole-body
25%
Functional Level
25%
Monogenic
25%
Behavioral Deficits
25%
Lysosomal Enzymes
25%
Vector Encoding
25%
Extended Life
25%
All-affected
25%
Pre-existing Immunity
25%
Full-coverage Restoration
25%
Biochemical Level
25%
Glycosaminoglycan Content
25%
Biochemistry, Genetics and Molecular Biology
Gene Therapy
100%
Liquid
100%
Mucopolysaccharidosis
100%
Enzyme Activity
75%
Lysosomal Storage Disease
50%
Enzyme
50%
Gene Expression
25%
Lifespan
25%
Blood Brain Barrier
25%
Target Organ
25%
Glycosaminoglycan
25%
Pharmacology, Toxicology and Pharmaceutical Science
Mucopolysaccharidosis
100%
Disease
75%
Lysosome Storage Disease
50%
Acetylglucosaminidase
50%
Glycosaminoglycan
25%
Nervous System Inflammation
25%
Lysosome Enzyme
25%
Monogenic Disorder
25%
Blood-Brain Barrier
25%
Neuroscience
Enzyme Activity
100%
Central Nervous System
66%
Acetylglucosaminidase
66%
Gene Expression
33%
Blood Brain Barrier
33%
Glycosaminoglycan
33%
Lysosome Enzyme
33%